A structure-based approach towards the identification of novel antichagasic compounds: Trypanosoma cruzi carbonic anhydrase inhibitors

References

• Alterio V, Di Fiore A, D’Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev 2012;112:4421–68.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Applications of carbonic anhydrases inhibitors in renal and central nervous system diseases. Expert Opin Ther Pat 2018;28:713–21.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas. Expert Opin Ther Pat 2018;28:709–12.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs 2018;27:963–70.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Supuran CT. Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008–2018). Expert Opin Ther Pat 2018;28:729–40.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81.
   PubMed Web of Science ®Google Scholar
• Domsic JF, Avvaru BS, Kim CU, et al. Entrapment of carbon dioxide in the active site of carbonic anhydrase II. J Biol Chem 2008;283:30766–71.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase activators. Future Med Chem 2018;10:561–73.
   PubMed Web of Science ®Google Scholar
• De Simone G, Supuran CT. (In)organic anions as carbonic anhydrase inhibitors. J Inorg Biochem 2012;111:117–29.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibition and the management of hypoxic tumors. Metabolites 2017;7:E48.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases and metabolism. Metabolites 2018;8:25.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbon- versus sulphur-based zinc binding groups for carbonic anhydrase inhibitors?. J Enzyme Inhib Med Chem 2018;33:485–95.
   PubMed Web of Science ®Google Scholar
• McKenna R, Supuran CT. Carbonic anhydrase inhibitors drug design. In: Frost SC, McKenna R, eds. Carbonic anhydrase mechanism regulation. Links to disease and industrial applications. Dordrecht: Springer; 2014:291–323.
   Google Scholar
• Briganti F, Pierattelli R, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Part 37. Novel classes of carbonic anhydrase inhibitors and their interaction with the native and cobalt-substituted enzyme: kinetic and spectroscopic investigations. Eur J Med Chem 1996;31:1001–10.
   Web of Science ®Google Scholar
• Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem 2016;31:345–60.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin Drug Discov 2017;12:61–88.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Structure and function of carbonic anhydrases. Biochem J 2016;473:2023–32.
   PubMed Web of Science ®Google Scholar
• Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767–77.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Vullo D, Manole G, et al. Designing of novel carbonic anhydrase inhibitors and activators. Curr Med Chem Cardiovasc Hematol Agents 2004;2:49–68.
   PubMedGoogle Scholar
• Supuran CT. Inhibition of carbonic anhydrase from Trypanosoma cruzi for the management of Chagas disease: an underexplored therapeutic opportunity. Future Med Chem 2016;8(3):311–24.
   PubMed Web of Science ®Google Scholar
• Chagas C. Nova tripanozomiaze humana: estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem. Mem Inst Oswaldo Cruz 1909;1:159.
   Google Scholar
• World Health Organization, Research priorities for Chagas disease, human African trypanosomiasis and leishmaniasis. World Health Organ Tech Rep Ser 2012;975:v–xii, 1–100.
   Web of Science ®Google Scholar
• Salomon CJ. First century of Chagas’ disease: an overview on novel approaches to nifurtimox and benznidazole delivery systems. J Pharm Sci 2012;101:888–94.
   PubMed Web of Science ®Google Scholar
• Pan P, Vermelho AB, Capaci Rodrigues G, et al. Cloning, characterization, and sulfonamide and thiol inhibition studies of an α-carbonic anhydrase from Trypanosoma cruzi, the causative agent of Chagas disease. J Med Chem 2013;56:1761–71.
   PubMed Web of Science ®Google Scholar
• Capasso C, Supuran CT. Anti-infective carbonic anhydrase inhibitors: a patent and literature review. Expert Opin Ther Pat 2013;23:693–704.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Capasso C. The eta-class carbonic anhydrases as drug targets for antimalarial agents. Expert Opin Ther Targets 2015;19:551–63.
   PubMed Web of Science ®Google Scholar
• Capasso C, Supuran CT. Bacterial, fungal and protozoan carbonic anhydrases as drug targets. Expert Opin Ther Targets 2015;19:1689–704.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Capasso C. Biomedical applications of prokaryotic carbonic anhydrases. Expert Opin Ther Pat 2018;28:745–54.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Capasso C. An overview of the bacterial carbonic anhydrases. Metabolites 2017;7:56.
   PubMed Web of Science ®Google Scholar
• Güzel-Akdemir Ö, Akdemir A, Pan P, et al. A class of sulfonamides with strong inhibitory action against the α-carbonic anhydrase from Trypanosoma cruzi. J Med Chem 2013;56:5773–81.
   PubMed Web of Science ®Google Scholar
• Meier A, Söding J. Automatic prediction of protein 3D structures by probabilistic multi-template homology modeling. PLoS Comput Biol 2015;11:e1004343.
   PubMed Web of Science ®Google Scholar
• Soding J, Biegert A, Lupas AN. The HHpred interactive server for protein homology detection and structure prediction. Nucleic Acids Res 2005;33:W244–8.
   PubMed Web of Science ®Google Scholar
• The UniProt Consortium, UniProt: the universal protein knowledgebase. Nucleic Acids Res 2017;45:D158–69.
   PubMed Web of Science ®Google Scholar
• Nivón LG, Moretti R, Baker D. A Pareto-Optimal Refinement Method for protein design scaffolds. PLoS One 2013;8:e59004.
   PubMed Web of Science ®Google Scholar
• Conway P, Tyka MD, DiMaio F, et al. Relaxation of backbone bond geometry improves protein energy landscape modeling. Protein Sci 2014;23:47–55.
   PubMed Web of Science ®Google Scholar
• Khatib F, Cooper S, Tyka MD, et al. Algorithm discovery by protein folding game players. Proc Natl Acad Sci USA 2011;108:18949–53.
   PubMed Web of Science ®Google Scholar
• Tyka MD, Keedy DA, André I, et al. Alternate states of proteins revealed by detailed energy landscape mapping. J Mol Biol 2011;405:607–18.
   PubMed Web of Science ®Google Scholar
• Case DA, Ben-ShalomI Y, Brozell SR, et al. 2018. AMBER 2018. San Francisco (CA): University of California.
   Google Scholar
• Peters MB, Yang Y, Wang B, et al. Structural survey of zinc-containing proteins and development of the Zinc AMBER Force Field (ZAFF). J Chem Theory Comput 2010;6:2935–47.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Cadoni R, Dumy P, et al. Carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani chagasi are inhibited by benzoxaboroles. J Enzyme Inhib Med Chem 2018;33:286–9.
   PubMed Web of Science ®Google Scholar
• Sketch M. 2014. Available from: http://www.chemaxon.com/products/marvin/marvinsketch/
   Google Scholar
• Santos-Martins D, Forli S, Ramos MJ, Olson AJ. AutoDock4 (Zn): an improved AutoDock force field for small-molecule docking to zinc metalloproteins. J Chem Inf Model 2014;54:2371–9.
   PubMed Web of Science ®Google Scholar
• Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785–91.
   PubMed Web of Science ®Google Scholar
• Gavernet L, Elvira JE, Samaja GA, et al. Synthesis and anticonvulsant activity of amino acid-derived sulfamides. J Med Chem 2009;52:1592–601.
   PubMed Web of Science ®Google Scholar
• Gavernet L, Barrios IA, Cravero MS, Bruno-Blanch LE. Design, synthesis, and anticonvulsant activity of some sulfamides. Bioorg Med Chem 2007;15:5604–14.
   PubMed Web of Science ®Google Scholar
• Villalba ML, Enrique AV, Higgs J, et al. Novel sulfamides and sulfamates derived from amino esters: synthetic studies and anticonvulsant activity. Eur J Pharmacol 2016;774:55–63.
   PubMed Web of Science ®Google Scholar
• Villalba ML, Palestro P, Ceruso M, et al. Sulfamide derivatives with selective carbonic anhydrase VII inhibitory action. Bioorg Med Chem 2016;24:894–901.
   PubMed Web of Science ®Google Scholar
• Murray AB, Lomelino CL, Supuran CT, McKenna R. “Seriously Sweet”: acesulfame K exhibits selective inhibition using alternative binding modes in carbonic anhydrase isoforms. J Med Chem 2018;61:1176–81.
   PubMed Web of Science ®Google Scholar
• Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem 1971;246:2561–73.
   PubMed Web of Science ®Google Scholar
• Menchise V, De Simone G, Alterio V, et al. Carbonic anhydrase inhibitors: stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II. J Med Chem 2005;48:5721–7.
   PubMed Web of Science ®Google Scholar
• Lolak N, Akocak S, Bua S, et al. Design and synthesis of novel 1,3-diaryltriazene-substituted sulfonamides as potent and selective carbonic anhydrase II inhibitors. Bioorg Chem 2018;77:542–47.
   PubMed Web of Science ®Google Scholar
• Akocak S, Lolak N, Bua S, et al. Discovery of novel 1,3-diaryltriazene sulfonamides as carbonic anhydrase I, II, VII, and IX inhibitors. J Enzyme Inhib Med Chem 2018;33:1575–80.
   PubMed Web of Science ®Google Scholar
• Winum JY, Temperini C, El Cheikh K, et al. Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. J Med Chem 2006;49:7024–31.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity. Expert Opin Ther Pat 2003;13:1545–50.
   Web of Science ®Google Scholar
• Ul-Hassan M, Scozzafava A, Chohan ZH, Supuran CT. Anhydrase inhibitors: metal complexes of a sulfanilamide derived Schiff base and their interaction with isozymes I, II and IV. J Enzyme Inhib 2001;16:499–505.
   PubMed Web of Science ®Google Scholar
• Pastorekova S, Casini A, Scozzafava A, et al. Carbonic anhydrase inhibitors: the first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg Med Chem Lett 2004;14:869–73.
   PubMed Web of Science ®Google Scholar
• Melis C, Meleddu R, Angeli A, et al. Isatin: a privileged scaffold for the design of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2017;32:68–73.
   PubMed Web of Science ®Google Scholar
• Gul HI, Mete E, Eren SE, et al. Designing, synthesis and bioactivities of 4-[3-(4-hydroxyphenyl)-5-aryl-4,5-dihydro-pyrazol-1-yl]benzenesulfonamides. J Enzyme Inhib Med Chem 2017;32:169–75.
   PubMed Web of Science ®Google Scholar
• Gul HI, Mete E, Taslimi P, et al. Synthesis, carbonic anhydrase I and II inhibition studies of the 1,3,5-trisubstituted-pyrazolines. J Enzyme Inhib Med Chem 2017;32:189–92.
   PubMed Web of Science ®Google Scholar
• Garaj V, Puccetti L, Fasolis G, et al. Carbonic anhydrase inhibitors: novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX. Bioorg Med Chem Lett 2005;15:3102–8.
   PubMed Web of Science ®Google Scholar
• da Silva Cardoso V, Vermelho AB, Ricci Junior E, et al. Antileishmanial activity of sulphonamide nanoemulsions targeting the β-carbonic anhydrase from Leishmania species. J Enzyme Inhib Med Chem 2018;33:850–7.
   PubMed Web of Science ®Google Scholar
• Akocak S, Lolak N, Vullo D, et al. Synthesis and biological evaluation of histamine Schiff bases as carbonic anhydrase I, II, IV, VII, and IX activators. J Enzyme Inhib Med Chem 2017;32:1305–12.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Acetazolamide for the treatment of idiopathic intracranial hypertension. Expert Rev Neurother 2015;15:851–6.
   PubMed Web of Science ®Google Scholar
• Şentürk M, Gülçin İ, Beydemir Ş, et al. In vitro inhibition of human carbonic anhydrase I and II isozymes with natural phenolic compounds. Chem Biol Drug Des 2011;77:494–9.
   PubMed Web of Science ®Google Scholar
• Kumar R, Sharma V, Bua S, et al. Synthesis and biological evaluation of benzenesulphonamide-bearing 1,4,5-trisubstituted-1,2,3-triazoles possessing human carbonic anhydrase I, II, IV, and IX inhibitory activity. J Enzyme Inhib Med Chem 2017;32:1187–94.
   PubMed Web of Science ®Google Scholar
• Bozdag M, Bua S, Osman SM, et al. Carbonic anhydrase I, II, IV and IX inhibition with a series of 7-amino-3,4-dihydroquinolin-2(1H)-one derivatives. J Enzyme Inhib Med Chem 2017;32:885–92.
   PubMed Web of Science ®Google Scholar
• Bertol E, Vaiano F, Mari F, et al. Advances in new psychoactive substances identification: the U.R.I.To.N. Consortium. J Enzyme Inhib Med Chem 2017;32:841–9.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors. Expert Opin Drug Metab Toxicol 2016;12:423–43.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Mincione F, Somma T, et al. A new approach to antiglaucoma drugs: carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology. J Enzyme Inhib Med Chem 2012;27:138–47.
   PubMed Web of Science ®Google Scholar
• Borras J, Scozzafava A, Menabuoni L, et al. Synthesis of water-soluble, topically effective intraocular pressure lowering aromatic/heterocyclic sulfonamide containing 8-*Quinoline-sulfonyl Moieties: is the tail more important than the ring? Bioorg Med Chem 1999;7:2397–406.
   PubMed Web of Science ®Google Scholar
• Stanica L, Gheorghiu M, Stan M, et al. Quantitative assessment of specific carbonic anhydrase inhibitors effect on hypoxic cells using electrical impedance assays. J Enzyme Inhib Med Chem 2017;32:1079–90.
   PubMed Web of Science ®Google Scholar
• Abdoli M, Angeli A, Bozdag M, et al. Synthesis and carbonic anhydrase I, II, VII, and IX inhibition studies with a series of benzo[d]thiazole-5- and 6-sulfonamides. J Enzyme Inhib Med Chem 2017;32:1071–8.
   PubMed Web of Science ®Google Scholar
• Bellera CL, Balcazar DE, Alberca L, et al. Identification of levothyroxine antichagasic activity through computer-aided drug repurposing. Sci World J 2014;2014:1–9.
   Web of Science ®Google Scholar
• Miranda CG, Solana ME, Lammel EM, et al. A flow cytometer-based method to simultaneously assess activity and selectivity of compounds against the intracellular forms of Trypanosoma cruzi. Acta Trop 2015;152:8–16.
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res 2000;28:235–42.
   PubMed Web of Science ®Google Scholar
• Šali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993;234:779–815.
   PubMed Web of Science ®Google Scholar
• Triballeau N, Acher F, Brabet I, et al. Virtual screening workflow development guided by the “receiver operating characteristic” curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. J Med Chem 2005;48:2534–47.
   PubMed Web of Science ®Google Scholar
• Bamber D. The area above the ordinal dominance graph and the area below the receiver operating characteristic graph. J Math Psychol 1975;12:387–415.
   Web of Science ®Google Scholar